HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
RA, bleeding
BLEEDING
This study in patients with moderate-to-severe active RA refractory to methotrexate treatment showed that TAS5315 may have some therapeutic benefit for patients who can tolerate bleeding; further analysis of the risk-benefit of TAS5315 for RA should be considered.